Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2012 Jan;123(1):1-11.
doi: 10.1007/s00401-011-0910-3. Epub 2011 Nov 20.

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach

Thomas J Montine  1 , Creighton H Phelps, Thomas G Beach, Eileen H Bigio, Nigel J Cairns, Dennis W Dickson, Charles Duyckaerts, Matthew P Frosch, Eliezer Masliah, Suzanne S Mirra, Peter T Nelson, Julie A Schneider, Dietmar Rudolf Thal, John Q Trojanowski, Harry V Vinters, Bradley T Hyman; National Institute on Aging; Alzheimer’s Association
Affiliations
Practice Guideline

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach

Thomas J Montine et al. Acta Neuropathol. 2012 Jan.

Abstract

We present a practical guide for the implementation of recently revised National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (AD). Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an "ABC" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid β deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C), and (3) more detailed approaches for assessing commonly co-morbid conditions such as Lewy body disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein (TDP)-43 immunoreactive inclusions. Recommendations also are made for the minimum sampling of brain, preferred staining methods with acceptable alternatives, reporting of results, and clinico-pathologic correlations.

PubMed Disclaimer

Figures

Figure 1
Figure 1. “ABC” Score for Alzheimer’s Disease Neuropathologic Change
Immunohistochemical detection of Aβ plaques in (a) neocortex with as an example of “A1”, (b) neostriatum as an example of “A2”, and (c) molecular layer of cerebellum as an example of “A3”. Scale bars are 500 microns. Anti-Aβ was antibody 6F/3D (Novocastra, Newcastle, United Kingdom).
Figure 2
Figure 2. “ABC” Score for Alzheimer’s Disease Neuropathologic Change
Immunohistochemical detection of neurofibrillary degeneration using phospho-tau antibody in the occipital cortex (Brodmann areas 17 and 18) as an example of “B3”. Scale bars equal (a) 150 microns and (b) 100 microns. PHF-1 antibody was generously provided by Dr. Peter Davies.
Figure 3
Figure 3. “ABC” Score for Alzheimer’s Disease Neuropathologic Change
Bielschowsky stain of neocortex shows (a) diffuse plaques but not neuritic plaques as an example of “C0”, and increasing density of neuritic plaques as examples of (b) “C1” (1 to 5 neuritic plaques per 1 mm2), (c) “C2” (> 6 but < 20 neuritic plaques per 1 mm2), and (d) “C3” (> 20 neuritic plaques per 1 mm2). Scale bars equal 100 microns.
Figure 4
Figure 4. Lewy Body Disease Classification
Immunohistochemical detection of α-synuclein in (a, scale bar 250 microns) dorsal motor nucleus of the vagus nerve and (b, scale bar 125 microns) substantia nigra neurons as examples of “Brainstem-predominant LBD”, (c, scale bar 50 microns) amygdala as an example of “Amygdala-predominant LBD”, (d, scale bar = 200 microns) anterior cingulate gyrus as an example of “Limbic (Transitional) LBD”, and (e - h, scale bar = 100 microns) superior temporal gyrus as an example of “Neocortical (diffuse) LBD” with varying levels of LBD severity: mild (e), moderate (f), severe (g), and very severe (h) [38]. Anti-alpha-synuclein was antibody KM51 (Novocastra, Newcastle, United Kingdom).
Figure 5
Figure 5. Microvascular Lesion
Cerebral cortex stained with (a) hematoxylin and eosin or for (b) immunohistochemical detection of glial fibrillary acidic protein reveals a microvascular lesion (MVL). Scale bar = 500 microns. Anti-GFAP was antibody 6F2 (DAKO, Glostrup, Denmark).
Figure 6
Figure 6. TDP-43 Inclusions
Immunohistochemical detection of TDP-43 in the dentate gyrus in a subject (a) without hippocampal sclerosis or (b) another case with hippocampal sclerosis that shows cytoplasmic inclusions in granule neurons that are (c) further highlighted by phospho-TDP-43. Scale bars equal 50 microns. Anti-TDP-43 was antibody 10782-2-AP (ProteinTech, Chicago IL, USA). Anti-phospho-TDP-43 was antibody TIP-PTD-M01 (pS409/410-1 from Cosmo Bio, Tokyo, Japan).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adler CH, Connor DJ, Hentz JG, et al. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord. 2010;25:642–6. - PMC - PubMed
    1. Alafuzoff I, Arzberger T, Al-Sarraj S, et al. Staging of neurofibrillary pathology in Alzheimer’s disease: a study of the BrainNet Europe Consortium. Brain Pathol. 2008;18:484–96. - PMC - PubMed
    1. Alafuzoff I, Parkkinen L, Al-Sarraj S, et al. Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2008;67:125–43. - PubMed
    1. Alafuzoff I, Pikkarainen M, Al-Sarraj S, et al. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2006;65:740–57. - PubMed
    1. Alafuzoff I, Thal DR, Arzberger T, et al. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2009;117:309–20. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding